Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction DOI
Matthias Pinter, Claudia Angela Maria Fulgenzi, David J. Pinato

и другие.

Gut, Год журнала: 2025, Номер unknown, С. gutjnl - 334928

Опубликована: Апрель 29, 2025

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given increased risk death from cirrhosis-related complications in liver dysfunction, pivotal phase III trials traditionally limited inclusion to Child-Pugh class A, where is more likely be attributed HCC progression. Therefore, Western guidelines recommend use systemic therapies primarily preserved function. However, and B are commonly encountered clinical practice, but due prospective evidence, there no clear guidance on their optimal management. In this recent advances article, we discuss how course cirrhosis can affect eligibility modern era HCC, elaborate strategies improve function by targeting tumour-related factors summarise current literature B. Based information, finally propose a algorithm systematically approach dysfunction practice.

Язык: Английский

Serum Osteopontin Enhances Hepatocellular Carcinoma Diagnosis and Predicts Anti-PD-L1 Immunotherapy Benefit DOI Creative Commons
Miantao Wu, Fei Zou, Shuangba He

и другие.

Journal of Hepatocellular Carcinoma, Год журнала: 2025, Номер Volume 12, С. 729 - 745

Опубликована: Апрель 1, 2025

Osteopontin (OPN), a phosphorylated glycoprotein encoded by SPP1, critical in hepatic inflammation and fibrosis, requires further investigation for its role on hepatocellular carcinoma (HCC) predictive value anti-programmed cell death ligand 1 (anti-PD-L1) immunotherapy responses. Publicly available datasets were utilized to explore OPN expression HCC. A retrospective cohort study involving 316 participants, recruited from January 2015 March 2017. Serum levels measured enzyme-linked immunosorbent assay. Diagnostic performance was assessed using receiver operating characteristic (ROC) curves, logistic regression model developed early HCC diagnosis. Prospective follow-up conducted 2017 2024 evaluate overall survival (OS) disease-free (DFS) Kaplan-Meier analyses. The benefit of anti-PD-L1 patients with patterns investigated. significantly elevated compared chronic liver disease healthy individuals (both p <0.001). area under the curve (AUC) 0.903, 88.2% sensitivity 83.3% specificity, superior AFP alone (AUC: 0.707). combined diagnostic integrating alpha-fetoprotein (AFP) aspartate aminotransferase (AST) enhanced accuracy 0.941). High indicated higher tumor burden predicted worse clinical outcomes (mean OS: 49.1 vs 75.1 months; mean DFS: 37.7 60.9 months, respectively; both log-rank Anti-PD-L1 prolonged (OS: 62.9 38.0 = 0.009; 48.7 28.6 0.033) high pattern. demonstrates standalone enhances conventional biomarker panels when AST. pattern identify likely immunotherapy, suggesting dual utility as biomarker.

Язык: Английский

Процитировано

0
PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers DOI

Peishuang Xu,

Chang Hong, Li Liu

и другие.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2025, Номер unknown, С. 189334 - 189334

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction DOI
Matthias Pinter, Claudia Angela Maria Fulgenzi, David J. Pinato

и другие.

Gut, Год журнала: 2025, Номер unknown, С. gutjnl - 334928

Опубликована: Апрель 29, 2025

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given increased risk death from cirrhosis-related complications in liver dysfunction, pivotal phase III trials traditionally limited inclusion to Child-Pugh class A, where is more likely be attributed HCC progression. Therefore, Western guidelines recommend use systemic therapies primarily preserved function. However, and B are commonly encountered clinical practice, but due prospective evidence, there no clear guidance on their optimal management. In this recent advances article, we discuss how course cirrhosis can affect eligibility modern era HCC, elaborate strategies improve function by targeting tumour-related factors summarise current literature B. Based information, finally propose a algorithm systematically approach dysfunction practice.

Язык: Английский

Процитировано

0